

DDA Registry

File Medical

DD/A 78-2930/7

27 OCT 1978

MEMORANDUM FOR: Legislative Counsel  
General Counsel  
Inspector General  
Director of Public Affairs

FROM: John F. Blake  
Deputy Director for Administration

SUBJECT: Coordination of Correspondence About  
Drug Experimentation

REFERENCE Multiple Addressee Memo from DDA,  
dtd 16 Aug 78; Subject: MKULTRA -  
Program to Identify Subjects of  
Agency-Sponsored Drug Testing  
(Copy Attached)

STATINTL

1. My memorandum of 16 August 1978 (Reference) named [REDACTED] as the MKULTRA locator program coordinator. His involvement in this program is now such that you may find it useful to coordinate with him any correspondence relating to drug experimentation. He would find it useful in the fulfillment of his responsibilities if such coordination were effected.

STATOTHR

2. Your cooperation will be appreciated. [REDACTED] is located in Room 4E27 Headquarters, he may be reached on [REDACTED]

STATINTL

/s/John F. Blake

John F. Blake

Att

Distribution:

Orig - Addse

1 - LC

1 - GC

1 - IG

1 - D/PA

1 - JFB Chrono

Approved For Release 2001/11/23 : CIA-RDP81-00142R000200100016-5

1 - SA/DDA

STATINTL

SA/DDA [REDACTED] dnb(24 )ct 78)

CONFIDENTIAL

Approved For Release 2001/11/23 : CIA-RDP81-00142R000200100016-5

DDA 78-2930/2

16 August 1978

MEMORANDUM FOR: Deputy Director for Science and Technology  
Inspector General  
Director of Technical Service  
Director of Security  
Director of Medical Services

FROM: John F. Blake  
Deputy Director for Administration

SUBJECT: MKULTRA - Program to Identify Subjects of  
Agency-Sponsored Drug Testing

REFERENCE: Memo dtd 24 Jul 78 to DCI via DDCI fr GC, same subj

1. Reference memorandum, a copy of which is attached for your information, contained recommendations to the DCI by the General Counsel on how to proceed on subject. The DCI has approved the recommendations. The General Counsel and myself, having mutually reviewed the almost infinite scope of this activity have agreed that the organization and conduct of this undertaking will be under my cognizance and, additionally, I will appoint a senior staff officer to be responsible for the matter.

2. The purpose of this memorandum is to inform you that I have appointed [REDACTED] as the MKULTRA locator program coordinator. At this time I would ask each addressee to notify my office by phone identifying their referent on this matter. [REDACTED] will then establish contact with that referent in order to acquaint himself with the file holdings and records that exist.

3. Our initial endeavors will be to try to size the scope of the problem. After that has been accomplished, we will implement the General Counsel's recommendation that a task force be created. It may be necessary to ask you to post a full-time detail for an unspecified period to the task force.

John F. Blake

Att

Approved For Release 2001/11/23 : CIA-RDP81-00142R000200100016-5

CONFIDENTIAL

DOWNGRADE TO A-IUO  
UPON REMOVAL OF ATT

SENDER WILL CHECK CLASSIFICATION TOP AND BOTTOM			
UNCLASSIFIED		CONFIDENTIAL	
		SECRET	
<b>OFFICIAL ROUTING SLIP</b>			
TO	NAME AND ADDRESS	DATE	INITIALS
1	DDA		
2			
3			
4			
5			
6			
ACTION		DIRECT REPLY	PREPARE REPLY
APPROVAL		DISPATCH	RECOMMENDATION
COMMENT		FILE	RETURN
CONCURRENCE		INFORMATION	SIGNATURE
<b>Remarks:</b>  Jack, Attached is another bit of correspondence for your signature. It is stimulated by the letter from Mr. Carlucci to Congressman Ryan, copy also attached, which I learned about almost by accident. A copy was sent to Frank Laubinger in OTS who is working with me out here nearly full time. He brought it to my attention when we found it in his box downtown. The letter was not coordinated with him before it was sent, either. There is no big deal here, but I would have suggested somewhat different wording. The facts are alright as far as they go, but they are not			
<b>FOLD HERE TO RETURN TO SENDER</b>			
FROM: NAME, ADDRESS AND PHONE NO.			DATE
UNCLASSIFIED		CONFIDENTIAL	
		SECRET	

STATINTL

complete.

Other experiments were conducted at [REDACTED] in which radio-active iodine uptake of the thyroid and T-4 uptake of red cells, and several other measures which we have developed, are being related to previously studied variables." This, I gather, is a standard kind of procedure and is not, on the surface, at least, drug related. I don't think this is worth a corrective letter to Ryan but it suggests that we need to be careful about how specific we get in our responses to correspondence.

R.H.W.

SENDER WILL CHECK CLASSIFICATION TOP AND BOTTOM		
UNCLASSIFIED	CONFIDENTIAL	SECRET

Approved For Release 2001/11/23 : CIA-RDP81-00142R000200100016-5

### OFFICIAL ROUTING SLIP

TO	NAME AND ADDRESS	DATE	INITIALS
1	EO/DDA	10/26	EF
2			
3	A/DDA	27 OCT 1978	h
4			
5	DDA	27 OCT 1978	7
6			

<input type="checkbox"/> ACTION	<input type="checkbox"/> DIRECT REPLY	<input type="checkbox"/> PREPARE REPLY
<input type="checkbox"/> APPROVAL	<input type="checkbox"/> DISPATCH	<input type="checkbox"/> RECOMMENDATION
<input type="checkbox"/> COMMENT	<input type="checkbox"/> FILE	<input type="checkbox"/> RETURN
<input type="checkbox"/> CONCURRENCE	<input type="checkbox"/> INFORMATION	<input type="checkbox"/> SIGNATURE

#### Remarks:

Jack,

Attached is another bit of correspondence for your signature. It is stimulated by the letter from Mr. Carlucci to Congressman Ryan, copy also attached, which I learned about almost by accident. A copy was sent to Frank Laubinger in OTS who is working with me out here nearly full time.

He brought it to my attention when we found it in his box downtown. The letter was not coordinated with him before it was sent, either. There is no big deal here, but I would have suggested somewhat different wording. The facts are alright as far as they go, but they are not

FOLD HERE TO RETURN TO SENDER

FROM: NAME, ADDRESS AND PHONE NO.	DATE

Approved For Release 2001/11/23 : CIA-RDP81-00142R000200100016-5

STATINTL

complete. Other experiments were conducted at  
[REDACTED] in which "radio-active iodine uptake of  
the thyroid and T-4 uptake of red cells, and  
several other measures which we have developed, are  
being related to previously studied variables."  
This, I gather, is a standard kind of procedure  
and is not, on the surface, at least, drug related.

I don't think this is worth a corrective  
letter to Ryan but it suggests that we need to be  
careful about how specific we get in our responses  
to correspondence.

R H W  
[REDACTED]

STATINTL